A strong bullish case is presented for Hims & Hers Health (HIMS), with the recent stock decline viewed as a significant buying opportunity ahead of a potential turnaround. The upcoming earnings call on February 23rd is a critical short-term catalyst that could reverse the stock's negative trend. Investors should monitor for updates on the company's $250 million share buyback program and early results from new growth areas like Testosterone and Menopause treatments. The core thesis is that the market is overly focused on GLP-1 risks while ignoring the strong core business and long-term AI potential. For those interested in similar beaten-down growth stocks, Oddity Tech (ODD) is highlighted as a quality company with a comparable business model.

Hims & Hers Health, Inc. (HIMS)

• The speaker is a long-term, committed bull on HIMS, viewing the recent stock decline as a buying opportunity and not a breakdown of the company's long-term potential.
• The stock is down 65% in six months, which the speaker attributes to two main factors:
  • Negative sentiment and narrative surrounding its GLP-1 weight-loss drug offerings.
  • A broader market sell-off in high-growth, small-cap stocks. The speaker notes that similar companies like Duolingo (DUOL) and Oddity Tech (ODD) are also down significantly.
• Short interest (the number of investors betting against the stock) is at an all-time high, indicating extremely negative market sentiment.
• The upcoming earnings call on Monday, February 23rd is presented as a major short-term catalyst that could determine if "the pain is over."

Key Points from the Upcoming Earnings Call (Feb 23rd)

• Revenue Growth: A key question is whether revenue growth has slowed down. The market is pricing in a catastrophic slowdown, while the speaker believes growth will be solid, even if it's below the current analyst consensus of 47%.
• Share Buyback Program: The company has a $250 million buyback program. The speaker is hopeful the company has been actively buying its own stock at these low prices and will be looking for a potential increase in the program to $500 million.
• Regulatory Issues: An update on the lawsuit from Novo Nordisk is expected. The speaker believes a trial is years away (post-2029) and that Novo has a strong incentive to settle. They also believe HIMS is safe from any legal action from Eli Lilly (LLY), which is seen as a very smart strategic move.
• New Growth Areas: The speaker is looking for early adoption numbers for new offerings like:
  • Testosterone and Menopause treatments (Hormone Replacement Therapy - HRT).
  • HIMS Labs, a direct-to-consumer lab testing service.
  • International expansion, particularly in Canada.

The Bullish Thesis

• Core Business is Strong: The company's primary revenue drivers are off-patent "blockbuster" treatments for Erectile Dysfunction (ED), hair loss, and anxiety (SSRIs). These are subscription-based and have sticky customers.
• Weight-Loss Business is Misunderstood: The speaker estimates that injectable GLP-1s are less than 25% of revenue. A significant, high-margin part of the weight-loss business is an oral pill based on Metformin, which is not subject to the same legal risks and is described as a "forgotten miracle compound."
• Excellent Financial Position: HIMS raised $1 billion in debt at 0% interest when the stock price was at a peak (around $62). This "war chest" of cash is now a major asset that can be used for buybacks, acquisitions, or new product development.
• The Long-Term Vision: Data & AI: The speaker's ultimate bullish case is that HIMS is building the future of healthcare.
  • The model bypasses insurance, allowing for innovation, clear pricing, and a customer-centric approach.
  • The future involves AI doctors, at-home health monitoring (health tech like smart scales/rings), and hyper-customized medication.
  • The key to winning is data. By collecting vast amounts of health data from labs, questionnaires, and tech devices, HIMS can train an AI to create a "digital twin" of each user, leading to superior, personalized health outcomes. This is compared to Tesla's (TSLA) data advantage in self-driving.

Takeaways

• The speaker presents a strong conviction, long-term bullish case for HIMS, suggesting the market is overly focused on short-term noise (the GLP-1 lawsuit) and ignoring the strength of the core business and its massive long-term potential in AI-driven healthcare.
• For current or potential investors, the February 23rd earnings call is a critical event. Pay close attention to management's guidance on revenue growth, their commentary on the buyback program, and any early metrics on new products like testosterone treatments.
• The investment thesis hinges on believing that HIMS can successfully transition from a seller of off-patent drugs to a comprehensive, data-driven health platform. The risk is that the market continues to punish the stock due to legal overhangs and competition, or that the company fails to execute on its ambitious AI-focused vision.

Comparative Growth Stocks

• The speaker mentions several other high-growth stocks to provide context for the sell-off in HIMS, arguing that it's a market-wide phenomenon, not just a HIMS-specific problem.

• Oddity Tech (ODD):

  • Described as the "closest stock to HIMS" in terms of business quality and playbook, but focused on the beauty industry.
  • Uses AI to create customized cosmetics, has high recurring revenue, and is "firing on all cylinders."
  • Despite a strong business with "no fud whatsoever," the stock is down 52%, similar to HIMS.

• Duolingo (DUOL):

  • Another high-growth stock that is down significantly.
  • The speaker notes the market has a bearish narrative that AI will kill Duolingo, a view the speaker dismisses.

• The Trade Desk (TTD):

  • Mentioned as another example of a high-growth stock that has seen a major decline, down 52% in six months.

Takeaways

• The significant drop in HIMS stock is not happening in a vacuum. Many high-quality, high-growth companies are experiencing similar or worse declines. This suggests the pressure is market-driven rather than purely a reflection of HIMS's business fundamentals.
• For investors looking for other opportunities in beaten-down growth stocks, Oddity Tech (ODD) is highlighted as a company with a strong, AI-driven business model similar to the speaker's vision for HIMS, but in the cosmetics space.

The GLP-1 Market (Novo Nordisk & Eli Lilly)

• The discussion centers on the competitive and legal landscape of the popular GLP-1 weight-loss drugs.

• Novo Nordisk (NVO):

  • The manufacturer of Ozempic/Wegovy (semaglutide).
  • Is currently suing HIMS for selling compounded versions of its drug.
  • The speaker believes Novo has an incentive to settle the lawsuit to focus on its bigger competitive threat, Eli Lilly.

• Eli Lilly (LLY):

  • The manufacturer of Mounjaro/Zepbound (tirzepatide).
  • The speaker emphasizes that HIMS made a very smart strategic decision to never offer compounded versions of Lilly's drug.
  • This is seen as a key advantage, as Lilly is an American company and the "jewel of healthcare in America," likely to receive favorable treatment from regulators.

Takeaways

• The legal battle with Novo Nordisk is a major risk and source of negative sentiment for HIMS. However, the speaker believes the long timeline and incentives to settle may mitigate the ultimate impact.
• HIMS's strategic decision to avoid conflict with Eli Lilly is a significant de-risking factor. It allows HIMS to operate without antagonizing the most powerful player in the American pharmaceutical market.
• Investors in this space should understand the complex dynamics between the major drug manufacturers (NVO, LLY) and the telehealth/compounding companies (HIMS). HIMS appears to be navigating this landscape strategically.